Faeth Therapeutics
Manufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
701 Tillery St 12 & 1010, Austin, Texas,...Website
www.faeththerapeutics.comRevenue
$6.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Faeth Therapeutics
Faeth Therapeutics is a clinical-stage biotechnology company developing multi-node therapies that block cancer growth signals while controlling tumor fuel supply, leveraging its AI-driven MetabOS platform to identify and exploit metabolic dependencies. In addition to advancing multiple solid-tumor studies, Faeth is advancing a translational program in Hereditary Tyrosinemia Type 1 (HT1), the first example of how its approach can extend beyond oncology into rare diseases. Founded in 2019Explore more
Faeth Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Faeth Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Faeth Therapeutics
Click to see if Faeth Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Faeth Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Faeth Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Faeth Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Faeth Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Faeth Therapeutics launches new products
Check out if Faeth Therapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Faeth Therapeutics
Compare insights from companies similar to Faeth Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Faeth Therapeutics
$6.6M
11-50
Private
$92M
2019
SK
Sydney KaufmanChief of Staff To the Chief Medical Officer
Company Profile Activity
Activity Insights
Faeth Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Faeth Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Faeth Therapeutics.
Faeth Therapeutics financials insights
Gather financial insights about Faeth Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Angel/Seed
$20M
Series A
$47M
2025
Other Financing Round
$25M
Faeth Therapeutics Tech Stack
A closer look at the technologies used by Faeth Therapeutics
Most Recent Scoops
Hiring Plans
Faeth Therapeutics has more open roles in Medical & Health than it has had at any time in the past 12 months.
Hiring Plans
Hiring Plans
Faeth Therapeutics has more open roles in Finance than it has had at any time in the past 12 months.
Hiring Plans
Hiring Plans
Faeth Therapeutics has more open roles in Engineering & Technical than it has had at any time in the past 12 months with an increased focus on technologies like Claude, and experience with PostgreSQL, GitHub Actions, Amazon AWS, React , and Playwright. Areas of expertise include: Test Data Generation, Wire Harnesses, OpenTelemetry, System Monitoring, Test Case, Gap Analysis, and Integral Calculus.
Hiring Plans
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Faeth Therapeutics News & Media
ESMO 2025: Faeth Therapeutics' Phase 2 DICE Trial Shows 34% Reduction in ... - FinancialContent
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus ChemotherapyFaeth Therapeutics Shows Preclinical Proof-of-Concept for Drug-Diet Combination to Treat Cancer, in Peer-Reviewed Publication
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, a clinical-stage biotechnology company integrating precision nutrition with combination therapies to address cancer metabolism, today announced publication of a preclinical proof-of-concept study supporting its rationale for targeting cancer metabolism through multi-node inhibition, including both therapeutics and an insulin-suppressing diet. The findings, published today in the peer-reviewed British Journal of Cancer, show that the three-pronFaeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer
AUSTIN, Texas & PHILADELPHIA--(BUSINESS WIRE)--Faeth Therapeutics (Faeth), a clinical-stage biotechnology company focused on metabolism, and The GOG Foundation, Inc. (GOG-F), a not-for-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and translational scientific research in the field of gynecologic malignancies, today announced the first patient has been dosed in its Phase 2 combination trial of PIKTOR, which is FTH-001 (serabelisib) and FTH-Faeth Therapeutics Appoints Dr. Stephen Hahn and Dr. Jayson Dallas to Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Faeth), a clinical biotechnology company focused on rethinking the science of cancer using metabolism, announced the appointment of Dr. Stephen Hahn, former FDA Commissioner and oncology expert, and Dr. Jayson Dallas, accomplished biotech leader and former CEO of Aimmune Therapeutics, to its Board of Directors. With these strategic additions, Faeth strengthens its leadership team as it advances its metabolic oncology therapies designed to impr
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Faeth Therapeutics
Sign Up For FreeTo access detailed company insights
Faeth Therapeutics is a clinical-stage biotechnology company developing multi-node therapies that block cancer growth signals while controlling tumor fuel supply, leveraging its AI-driven MetabOS platform to identify and exploit metabolic dependencies. In addition to advancing multiple solid-tumor studies, Faeth is advancing a translational program... Read More
